Related Experiment Video
Updated: Sep 2, 2025
08:57
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
27.2K
Seeing is believing: Identifying remyelination in the central nervous system
M F E Hill1, N G Cunniffe2, R J M Franklin1
1Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AH, UK; Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK.
Current Opinion in Pharmacology
|August 4, 2022
Summary
Remyelination restores myelin in demyelinating diseases like multiple sclerosis (MS). Current preclinical and clinical measures for assessing remyelination are difficult to translate, hindering therapeutic development.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Clinical Neurology
Background:
- Remyelination is crucial for restoring function in demyelinating disorders like multiple sclerosis (MS).
- Oligodendrocyte progenitor cells (OPCs) differentiate into myelinating oligodendrocytes (OLs) in the central nervous system (CNS).
- Several therapies targeting remyelination are in clinical trials, building on preclinical successes.
Purpose of the Study:
- To review current methods for assessing remyelination in preclinical and clinical settings.
- To identify challenges in translating preclinical findings to clinical outcomes.
- To highlight potential therapeutic candidates for enhancing remyelination.
Main Methods:
- Review of existing literature on remyelination assessment techniques.
- Analysis of translational barriers between preclinical models and human trials.
- Identification and discussion of promising pro-regenerative therapies.
Main Results:
- Preclinical measures of remyelination do not consistently predict clinical outcomes.
- Paraclinical measures used in human trials are difficult to implement in small animal models.
- A gap exists in standardized, translatable outcome measures for remyelination therapies.
Conclusions:
- Bridging the translational gap in remyelination assessment is critical for advancing MS therapies.
- Developing standardized and applicable outcome measures is essential for successful clinical translation.
- Further research into novel assessment tools may accelerate the development of effective remyelination treatments.
Related Concept Videos
01:25Nervous Tissue: Myelin
3.0K
The myelin sheath is a multilayered lipid and protein covering that insulates the axon of a neuron, enhancing the speed of nerve impulse conduction. Axons without this sheath are referred to as unmyelinated. Two types of neuroglia, Schwann cells in the peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS) are responsible for producing myelin sheaths.
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...
3.0K
01:15Neurogenesis and Regeneration of Nervous Tissue
986
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
986